## Joshua A Barocas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4385431/publications.pdf

Version: 2024-02-01

430874 477307 1,047 63 18 29 citations h-index g-index papers 65 65 65 1319 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Initiation of HIV pre-exposure prophylaxis among youth in the United States, 2015–2018. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2023, 35, 431-436.	1.2	3
2	Behavioral Risk Factors for HIV Infection in Hospitalized Persons Who Co-use Stimulants and Opioids. AIDS and Behavior, 2022, 26, 1047-1055.	2.7	1
3	Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study. Clinical Infectious Diseases, 2022, 75, e1112-e1119.	5.8	23
4	Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. Lancet Public Health, The, 2022, 7, e56-e64.	10.0	26
5	100–100–100: a new, ambitious treatment target to end the HIV and hepatitis C epidemics. Lancet Public Health, The, 2022, 7, e98-e99.	10.0	0
6	Factors associated with opioid-involved overdose among previously incarcerated people in the U.S.: A community engaged narrative review. International Journal of Drug Policy, 2022, 100, 103534.	3.3	6
7	Crisis stabilization units for jail diversion: A preliminary assessment of patient characteristics and outcomes Psychological Services, 2022, 19, 630-636.	1.5	3
8	Can I Safely Discharge a Patient with a Substance Use Disorder Home with a Peripherally Inserted Central Catheter?. , 2022, $1$ , .		8
9	Costâ€effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12256.	3.7	9
10	Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use–Associated Infective Endocarditis. JAMA Network Open, 2022, 5, e220541.	5.9	7
11	Populationâ€level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and costâ€effectiveness analysis. Addiction, 2022, 117, 2450-2461.	3.3	3
12	Modeling the costâ€effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction, 2022, , .	3.3	4
13	Stimulant-related incident surveillance using emergency medical service records in Massachusetts, 2013–2020 Drug and Alcohol Dependence, 2022, 235, 109460.	3.2	0
14	Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. Clinical Infectious Diseases, 2021, 73, e3661-e3669.	5.8	33
15	It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs. Clinical Infectious Diseases, 2021, 72, 1401-1403.	5.8	2
16	Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis. Clinical Infectious Diseases, 2021, 72, 472-478.	5.8	42
17	Caring for COVID's Most Vulnerable Victims: a Safety-Net Hospital Responds. Journal of General Internal Medicine, 2021, 36, 1006-1010.	2.6	6
18	Addressing the COVID-19 Pandemic Among Persons Experiencing Homelessness: Steps to Protect a Vulnerable Population. Journal of General Internal Medicine, 2021, 36, 1416-1417.	2.6	12

#	Article	IF	CITATIONS
19	Projected Estimates of Opioid Mortality After Community-Level Interventions. JAMA Network Open, 2021, 4, e2037259.	5.9	37
20	Implementation of a Recuperation Unit and Hospitalization Rates Among People Experiencing Homelessness With COVID-19. JAMA Network Open, 2021, 4, e212826.	5.9	5
21	Housing Is an Essential Part of Health Care—"Treat †Em and House †Em†JAMA Network Open, 2021, 4 e210635.	<sup>1</sup> , <sub>5.9</sub>	1
22	Opioid use disorder and overdose among youth following an initial opioid prescription. Addiction, 2021, 116, 2790-2800.	3.3	9
23	Time to SARS-CoV-2 PCR Clearance in Immunocompromising Conditions: Is Test-Based Removal From Isolation Necessary in Severely Immunocompromised Individuals?. Open Forum Infectious Diseases, 2021, 8, ofab164.	0.9	13
24	A Descriptive Comparison of Substance Use Services in Recovery and Isolation Sites for People Experiencing Homelessness During the COVID-19 Pandemic, Boston and Toronto. Public Health Reports, 2021, 136, 532-537.	2.5	7
25	The Urgent Public Health Need to Develop "Crisis Standards of Housing― Lessons From the COVID-19 Pandemic. American Journal of Public Health, 2021, 111, 1207-1209.	2.7	1
26	Association of skin infections with sharing of injection drug preparation equipment among people who inject drugs. International Journal of Drug Policy, 2021, 94, 103198.	3.3	8
27	Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug and Alcohol Dependence, 2021, 225, 108764.	3.2	25
28	Business Not as Usual â€" Covid-19 Vaccination in Persons with Substance Use Disorders. New England Journal of Medicine, 2021, 384, e6.	27.0	31
29	Healthcare Providers' Views on Hepatitis C Testing and Counseling Among Sexual Partners of Hepatitis C–Infected Persons. Infectious Diseases in Clinical Practice, 2021, 29, e151-e153.	0.3	1
30	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. International Journal of Drug Policy, 2021, 96, 103469.	3.3	7
31	An Economic Analysis of the Cost of a Regional Crisis Stabilization Unit. Journal of Correctional Health Care, 2021, , .	0.5	1
32	58. Cost-Effectiveness of Emerging Antibiotic Strategies for the Treatment of Drug-Use Associated Infective Endocarditis. Open Forum Infectious Diseases, 2021, 8, S40-S40.	0.9	0
33	Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases. Clinical Infectious Diseases, 2020, 70, 968-972.	5.8	45
34	Assessment of Oropharyngeal Specimens for Discontinuation of Transmission-Based COVID-19 Precautions. Open Forum Infectious Diseases, 2020, 7, ofaa382.	0.9	1
35	Estimates of opioid use disorder prevalence from a regression-based multi-sample stratified capture-recapture analysis. Drug and Alcohol Dependence, 2020, 217, 108337.	3.2	13
36	Infective Endocarditis in Persons Who Use Drugs. Infectious Disease Clinics of North America, 2020, 34, 479-493.	5.1	14

#	Article	IF	Citations
37	Opioid overdose and inpatient care for substance use disorder care in Massachusetts. Journal of Substance Abuse Treatment, 2020, 112, 42-48.	2.8	13
38	Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. Drug and Alcohol Dependence, 2020, 217, 108336.	3.2	8
39	Commentary on Jones et al . (2020): Using indirect estimation methods of drug use prevalence to address racial and ethnic health disparities. Addiction, 2020, 115, 2405-2406.	3.3	2
40	Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug and Alcohol Dependence, 2020, 215, 108207.	3.2	16
41	Prevalence of Covid-19 Infection and Subsequent Cohorting in a Residential Substance Use Treatment Program in Boston, MA. Journal of Addiction Medicine, 2020, 14, e261-e263.	2.6	6
42	Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities. Journal of Substance Abuse Treatment, 2020, 118, 108103.	2.8	13
43	Case 21-2020: A 66-Year-Old Homeless Man with Covid-19. New England Journal of Medicine, 2020, 383, 170-178.	27.0	12
44	USPSTF's Hepatitis C Screening Recommendation—A Necessary Step to Tackling an Evolving Epidemic. JAMA Network Open, 2020, 3, e200538.	5.9	5
45	Hospitalization outcomes of people who use drugs: One size does not fit all. Journal of Substance Abuse Treatment, 2020, 112, 23-28.	2.8	23
46	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. JAMA Network Open, 2020, 3, e2029676.	5.9	17
47	Incidence and Characteristics of Nonfatal Opioid Overdose Among Youths Aged 11 to 24 Years by Sex. JAMA Network Open, 2020, 3, e2030201.	5.9	22
48	Commentary on Irvine <i>et al</i> . (2019): Barriers to implementing a successful roadmap for preventing opioidâ€related overdose deaths. Addiction, 2019, 114, 1614-1615.	3.3	4
49	Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral na $ ilde{A}$ -ve persons with alcohol use in Russia. PLoS ONE, 2019, 14, e0218852.	2.5	14
50	Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug and Alcohol Dependence, 2019, 200, 59-63.	3.2	103
51	Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. International Journal of Drug Policy, 2019, 72, 160-168.	3.3	23
52	Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States. Clinical Infectious Diseases, 2018, 67, 549-556.	5.8	53
53	1946. Heterogeneous Hospitalization Outcomes of People Who Use Drugs: The Type of Drug(s) Used Matters. Open Forum Infectious Diseases, 2018, 5, S561-S561.	0.9	0
54	2232. Zinc deficiency and advanced liver fibrosis among HIV/HCV co-infected persons in Russia. Open Forum Infectious Diseases, 2018, 5, S660-S660.	0.9	0

#	Article	IF	CITATIONS
55	Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011–2015: A Capture–Recapture Analysis. American Journal of Public Health, 2018, 108, 1675-1681.	2.7	109
56	Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults. JAMA Internal Medicine, 2017, 177, 880.	5.1	21
57	<i>Editorial Commentary</i> : Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis. Clinical Infectious Diseases, 2017, 64, 100-101.	5.8	1
58	Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations. Health Affairs, 2017, 36, 2142-2150.	5.2	34
59	Acceptability of Rapid Point-of-Care Hepatitis C Tests Among People Who Inject Drugs and Utilize Syringe-Exchange Programs. Open Forum Infectious Diseases, 2016, 3, ofw075.	0.9	12
60	High uptake of naloxone-based overdose prevention training among previously incarcerated syringe-exchange program participants. Drug and Alcohol Dependence, 2015, 154, 283-286.	3.2	19
61	Advance directives among people living with HIV: room for improvement. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 370-377.	1.2	10
62	1608Low rates of advance directive completion among HIV-infected patients: a retrospective analysis. Open Forum Infectious Diseases, 2014, 1, S429-S429.	0.9	0
63	Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduction Journal, 2014, 11, 1.	3.2	96